BRPI0919545A2 - anticorpos que se ligam a il-18 e métodos de purificar os mesmos - Google Patents

anticorpos que se ligam a il-18 e métodos de purificar os mesmos

Info

Publication number
BRPI0919545A2
BRPI0919545A2 BRPI0919545A BRPI0919545A BRPI0919545A2 BR PI0919545 A2 BRPI0919545 A2 BR PI0919545A2 BR PI0919545 A BRPI0919545 A BR PI0919545A BR PI0919545 A BRPI0919545 A BR PI0919545A BR PI0919545 A2 BRPI0919545 A2 BR PI0919545A2
Authority
BR
Brazil
Prior art keywords
antibodies
purifying
bind
methods
Prior art date
Application number
BRPI0919545A
Other languages
English (en)
Inventor
Johanna Gervais
Qing Huang
Robert K Hickman
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of BRPI0919545A2 publication Critical patent/BRPI0919545A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
BRPI0919545A 2008-10-20 2009-10-20 anticorpos que se ligam a il-18 e métodos de purificar os mesmos BRPI0919545A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19675108P 2008-10-20 2008-10-20
PCT/US2009/061326 WO2010048183A1 (en) 2008-10-20 2009-10-20 Antibodies that bind to il-18 and methods of purifying the same

Publications (1)

Publication Number Publication Date
BRPI0919545A2 true BRPI0919545A2 (pt) 2015-12-08

Family

ID=41790633

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0919545A BRPI0919545A2 (pt) 2008-10-20 2009-10-20 anticorpos que se ligam a il-18 e métodos de purificar os mesmos

Country Status (16)

Country Link
US (1) US20100150864A1 (pt)
EP (1) EP2346901A1 (pt)
JP (1) JP2012506239A (pt)
KR (1) KR20110071011A (pt)
CN (1) CN102257007A (pt)
AU (1) AU2009307728B2 (pt)
BR (1) BRPI0919545A2 (pt)
CA (1) CA2739077A1 (pt)
IL (1) IL211867A0 (pt)
MX (1) MX2011004199A (pt)
NZ (1) NZ592094A (pt)
RU (1) RU2514657C2 (pt)
SG (1) SG195574A1 (pt)
TW (1) TW201030016A (pt)
WO (1) WO2010048183A1 (pt)
ZA (1) ZA201102550B (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0920572A8 (pt) 2008-10-20 2015-10-27 Abbott Lab Inativação viral durante a purificação dos anticorpos
NZ592095A (en) 2008-10-20 2013-01-25 Abbott Lab Isolation and purification of il-12 and tnf-alpha antibodies using protein a affinity chromatography
ES2645692T3 (es) 2008-11-11 2017-12-07 The Board Of Regents,The University Of Texas System Microcápsulas de rapamicina y su uso para el tratamiento del cáncer
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
EP2627425A4 (en) * 2010-10-11 2014-11-05 Abbvie Inc METHODS OF PURIFYING PROTEINS
AU2011325341B2 (en) 2010-11-01 2015-12-17 Dpx Holdings B.V. Single unit ion exchange chromatography antibody purification
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
SG11201407809QA (en) 2012-05-31 2014-12-30 Agency Science Tech & Res Chromatographic purification of immunoglobulin g preparations with particles having multimodal functionalities
EP2864346B1 (en) * 2012-06-21 2018-10-17 Synthon Biopharmaceuticals B.V. Method of purifying an antibody
GB201213968D0 (en) * 2012-08-06 2012-09-19 Isis Innovation Prevention and treatment of osteoarthritis
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
US9376489B2 (en) 2012-09-07 2016-06-28 Novartis Ag IL-18 binding molecules
HK1207960A1 (en) 2013-03-12 2016-02-19 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
WO2014160328A1 (en) 2013-03-13 2014-10-02 The Board Of Regents Of The University Of Texas System Mtor inhibitors for prevention of intestinal polyp growth
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
CN120904322A (zh) 2013-09-13 2025-11-07 豪夫迈·罗氏有限公司 包含纯化的重组多肽的方法和组合物
RU2016107435A (ru) 2013-09-13 2017-10-18 Дженентек, Инк. Композиции и способы обнаружения и количественного определения белка клеток-хозяев в клеточных линиях и рекомбинантные полипептидные продукты
CN106103720A (zh) * 2013-10-03 2016-11-09 武田疫苗股份有限公司 自细胞系检测和除去弹状病毒的方法
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
EP3089737B1 (en) 2013-12-31 2021-11-03 Rapamycin Holdings, LLC Oral rapamycin nanoparticle preparations and use
WO2016153983A1 (en) * 2015-03-20 2016-09-29 Bristol-Myers Squibb Company Use of dextran for protein purification
KR20190057083A (ko) * 2016-10-06 2019-05-27 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 공정 불순물에 대한 결합이 감소된 항체
GB201721846D0 (en) * 2017-12-22 2018-02-07 Arecor Ltd Novel composition
JP6892180B2 (ja) 2018-12-03 2021-06-23 株式会社ｍＡｂＰｒｏｔｅｉｎ 活性型インターロイキン−１８タンパク質のネオエピトープを認識する抗体、及びその応用
AU2020279395B2 (en) 2019-05-22 2025-08-28 Biovie Inc. Formulations of terlipressin
EP4061825A1 (en) 2019-11-22 2022-09-28 MorphoSys AG Method to increase antibody yield during ion exchange chromatography
KR20230110291A (ko) 2020-11-18 2023-07-21 노파르티스 아게 Nlrc4-gof 염증복합체병증의 치료에 사용하기 위한 이중특이적 항체
WO2023286694A1 (ja) 2021-07-13 2023-01-19 国立大学法人東海国立大学機構 炎症性腸疾患を治療するための医薬組成物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5429746A (en) * 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
US5853714A (en) * 1995-03-27 1998-12-29 Genetics Institute, Inc. Method for purification of IL-12
ATE256476T1 (de) * 1996-11-15 2004-01-15 Kennedy Inst Of Rheumatology Unterdrückung von tnfalpha und il-12 in der therapie
US6955917B2 (en) * 1997-06-20 2005-10-18 Bayer Healthcare Llc Chromatographic method for high yield purification and viral inactivation of antibodies
IL121900A (en) * 1997-10-07 2001-12-23 Omrix Biopharmaceuticals Ltd A method for the purification of immunoglobulins
US6914128B1 (en) * 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
CA2399148A1 (en) * 2000-02-10 2001-08-16 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
GB0020685D0 (en) * 2000-08-22 2000-10-11 Novartis Ag Organic compounds
US20040092719A1 (en) * 2002-09-17 2004-05-13 Eszter Birck-Wilson Isolation of immunoglobulin molecules that lack inter-heavy chain disulfide bonds
US8728828B2 (en) * 2004-12-22 2014-05-20 Ge Healthcare Bio-Sciences Ab Purification of immunoglobulins
EP1869067A1 (en) * 2005-04-11 2007-12-26 Medarex, Inc. Protein purification using hcic amd ion exchange chromatography
ZA200710330B (en) * 2005-06-17 2009-12-30 Wyeth Corp Methods of purifying FC region containing proteins
CN102887955A (zh) * 2006-04-05 2013-01-23 艾博特生物技术有限公司 抗体纯化
SI2061803T2 (sl) * 2006-08-28 2023-01-31 Ares Trading S.A. Postopek za čiščenje proteinov, ki vsebujejo FC
WO2009058769A1 (en) * 2007-10-30 2009-05-07 Schering Corporation Purification of antibodies containing hydrophobic variants

Also Published As

Publication number Publication date
AU2009307728B2 (en) 2014-12-11
CA2739077A1 (en) 2010-04-29
US20100150864A1 (en) 2010-06-17
NZ592094A (en) 2013-01-25
EP2346901A1 (en) 2011-07-27
ZA201102550B (en) 2012-01-25
MX2011004199A (es) 2011-05-24
RU2514657C2 (ru) 2014-04-27
CN102257007A (zh) 2011-11-23
TW201030016A (en) 2010-08-16
RU2011120173A (ru) 2012-11-27
KR20110071011A (ko) 2011-06-27
WO2010048183A1 (en) 2010-04-29
AU2009307728A1 (en) 2010-04-29
SG195574A1 (en) 2013-12-30
IL211867A0 (en) 2011-06-30
JP2012506239A (ja) 2012-03-15

Similar Documents

Publication Publication Date Title
BRPI0919545A2 (pt) anticorpos que se ligam a il-18 e métodos de purificar os mesmos
CY2022036I1 (el) Πρωτεϊνες δεσμευομενες με αντιγονο ικανες να δεσμευονται με θυμικη στρωματικη λεμφοποιητινη
CY2024018I1 (el) Αντι-pd-l1 αντισωματα και χρηση αυτων για την ενισχυση της λειτουργιας τ-κυτταρων
BRPI0919547A2 (pt) anticorpos que se ligam a il-12 e métodos de purificação do mesmo
PT2552955T (pt) Anticorpos com afinidade modificada para fcrn que promovem a depuração de antigénios
CY2017021I1 (el) Υψηλης συναφειας ανθρωπινα αντισωματα προς pcsk9
HRP20181645T1 (hr) Monoklonalna antitijela prema progastrinu i njihove upotrebe
LTC2356151I2 (lt) Didelio afiniškumo žmogaus antikūnai prieš žmogaus IK-4 receptorius
HRP20190047T1 (hr) Protutijela koja se vežu na csf1r
BRPI0916973A2 (pt) anticorpos para ccr2
HRP20150282T1 (hr) Purifikacija protutijela pomoä†u kromatografije kationskom izmjenom
LT2975051T (lt) Lengvai išskiriami bispecifiniai antikūnai su natyvios formos imunoglobulinu
EP3064512C0 (en) ANTIBODIES AGAINST CLDN6
PL2427212T3 (pl) Przeciwciała anty cd-100 i sposoby ich zastosowania
DK2435568T3 (da) Samling af syntetiske antistoffer til behandling af sygdom
IL287311A (en) Antibodies and processes for preparing the same
BR112013013043A2 (pt) proteínas de repetição concebidas que se ligam á albumina sérica
HUE037140T2 (hu) Humán GDF8-hoz kötõdõ ellenanyagok
BRPI0819205A2 (pt) Anticorpos humanizados contra tl1a
PL2990421T3 (pl) Przeciwciała anty-ceacam1 oraz sposoby ich stosowania
DK3338799T3 (da) Antistoffer til il-6 og anvendelse deraf
HUE043556T2 (hu) Nehézlánc antitesteket elõállító egerek
HUE036477T2 (hu) Monoklonális anti-GT468 antitestek rák kezeléséhez
HRP20170234T1 (hr) Molekule antitijela koje imaju specifično vezanje za ljudski il-13
EP2643019A4 (en) ANTIBODIES AGAINST NOTUM PECTINACETYLESTERASE

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B25A Requested transfer of rights approved

Owner name: ABBVIE INC. (US)

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.